Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
14.93 USD | -1.06% |
|
-1.06% | -12.49% |
Summary
- On the basis of various fundamental qualitative criteria, the company appears to be particularly poorly ranked from a medium and long-term investment perspective.
- From a short-term investment perspective, the company presents a deteriorated fundamental configuration.
Strengths
- The company's share price in relation to its net book value makes it look relatively cheap.
- Over the past year, analysts have regularly revised upwards their sales forecast for the company.
- The average target price set by analysts covering the stock is above current prices and offers a tremendous appreciation potential.
Weaknesses
- Low profitability weakens the company.
- The company is in a hindered financial situation with significant debt and rather low EBITDA levels.
- For the past year, analysts have significantly revised downwards their profit estimates.
- For the last twelve months, the analysts covering the company have given a bearish overview of EPS estimates, resulting in frequent downward revisions.
- Over the past four months, analysts' average price target has been revised downwards significantly.
- Sales estimates for the next fiscal years vary from one analyst to another. This clearly highlights a lack of visibility into the company's future activity.
- The price targets of various analysts who make up the consensus differ significantly. This reflects different assessments and/or a difficulty in valuing the company.
Ratings chart - Surperformance
Sector: Medical Equipment, Supplies & Distribution
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
-12.49% | 5.25B | - | ||
-3.95% | 184B | C+ | ||
-0.90% | 105B | C | ||
-2.27% | 68.87B | A | ||
+15.24% | 46.61B | B- | ||
-6.00% | 46.39B | B- | ||
+6.01% | 40.74B | B+ | ||
+20.65% | 31.26B | B | ||
-5.50% | 24.24B | A- | ||
+11.94% | 24B | A- |
Financials
Valuation
Momentum
Consensus
Business Predictability
Technical analysis
- Stock Market
- Equities
- BLCO Stock
- Ratings Bausch + Lomb Corporation